Entera Bio Ltd. Cash ROIC

Cash ROIC of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Cash ROIC growth rates and interactive chart.

Highlights and Quick Summary

  • Annual Cash ROIC for 2019 was -33.5% (a -27.66% decrease from previous year)
  • Annual Cash ROIC for 2018 was -46.31% (a -255.77% decrease from previous year)
  • Twelve month Cash ROIC ending June 29, 2020 was -64.67% (a 57.42% increase compared to previous quarter)
  • Twelve month trailing Cash ROIC decreased by -18.89% year-over-year
Trailing Cash ROIC for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
-64.67% -41.08% -32.76% -79.73%
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Cash ROIC of Entera Bio Ltd.

Most recent Cash ROICof ENTX including historical data for past 10 years.

Interactive Chart of Cash ROIC of Entera Bio Ltd.

Entera Bio Ltd. Cash ROIC for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 -33.5%
2018 -46.31%
2017 29.73%

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.